 |
 |
^^^^^^GREETINGS FROM^^^^^^^^^^ Ivan Suzman 47/10 [log in to unmask] Portland, Maine land of lighthouses 56 deg. F leaves falling *********************************************************** Hi Listfriends, Three Ropinerole questions: 1. Can any PWP's with experience with Ropinerole please comment on its effects on YOU, for better or worse? 2. What receptor sites are involved? Where are these in the brain? 3. What is the difference between D1, D2 and D3 receptor sites? Thank you! IVAN (one of your 1500 classmates in AGONISTS 101: An introduction to ropeinerole) On Tue, 23 Sep 1997 08:25:20 -0400 janet paterson <[log in to unmask]> writes: >------------------------------------------------------------------------- >SmithKline Beecham's Drug For Parkinson's Disease Clears FDA >------------------------------------------------------------------------- > >WESTPORT, Sep 23 (Reuters) - Ropinirole hydrochloride (Requip, >SmithKline >Beecham) has been approved by the FDA for treatment of patients with >Parkinson's disease. > >According to a company press release, ropinirole hydrochloride, a >second >generation dopamine agonist, has been cleared for marketing both as >initial >therapy for early signs and symptoms of Parkinson's disease and as >adjunctive therapy for patients with advanced Parkinson's disease who >are >already taking levodopa. > >"Requip is a significant advancement that may change the way >physicians >treat this complicated disease," Dr. Ray Watts of Emory said in the >press >release. > >"Requip allows physicians to delay the use of levodopa... which may be >associated with severe motor fluctuations after long-term use." > >In clinical trials, patients with mild to moderate Parkinson's disease >treated with ropinirole experienced significantly greater improvement >in >motor score compared with placebo-treated patients. > >In a separate trial, patients with advanced Parkinson's disease were >able >to reduce their requirement for levodopa while taking ropinirole. The >drug >was well-tolerated in both trials. > >Westport Newsroom 203 319 2700 >Copyright 1997 Reuters Limited. ><http://www.reutershealth.com/news/docs/199709/19970923rgc.html> >------------------------------------------------------------------------- > >[log in to unmask] >